NCT00820742View on ClinicalTrials.gov

Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Macugen

Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00820742 - Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration. | Biotech Hunter | Biotech Hunter